Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study Dominic G. Rothwell , Mahmood Ayub , Natalie Cook , Fiona Thistlethwaite , Louise Carter , Emma Dean , Nigel Smith , Shaun Villa , Joanne Dransfield , Alexandra Clipson , Daniel White , Kamrun Nessa , Saba Ferdous , Matthew Howell , Avinash Gupta , Bedirhan Kilerci , Sumitra Mohan , Kris Frese , Sakshi Gulati , Crispin Miller , Allan Jordan , Helen Eaton , Nicholas Hickson , Ciara O’Brien , Donna Graham , Claire Kelly , Sreeja Aruketty , Robert Metcalf , Jaseela Chiramel , Nadina Tinsley , Alexander J. Vickers , Roopa Kurup , Hannah Frost , Julie Stevenson , Siobhan Southam , Dónal Landers , Andrew Wallace , Richard Marais , Andrew M. Hughes , Ged Brady , Caroline Dive , Matthew G. Krebs NATURE MEDICINE（2019）
摘要
Sequencing of circulating tumor DNA from cancer patients is a cost-efficient approach with turnaround time compatible with clinical practice to inform treatment decision-making in a phase 1 trial setting
更多 查看译文
关键词
ctdna, clinical trials, patient selection
AI 理解论文
溯源树
样例
